Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application.

Listing of Claims:

1-53. (Canceled)

54. (Currently amended) A fusion protein comprising an antigen of an influenza virus, or an antigenic portion thereof, and a stress protein, or a portion thereof, wherein the antigen of the influenza virus is nucleoprotein, neuraminidase, M1, M2, PB1, PB2, or PA, the stress protein is an Hsp100-200, an Hsp100, an Hsp90, Lon, an Hsp70, an Hsp60, TF55, an Hsp40, an FKBP, a cyclophilin, an Hsp20-30, ClpP, GrpE, Hsp10, ubiquitin, calnexin, or a protein disulfide isomerase, and the fusion protein induces an immune response against the antigen in a mammal to whom the fusion protein is administered.

55-56. (Canceled)

57. (Previously presented) The fusion protein of claim 54, wherein the antigen of the influenza virus is nucleoprotein.

58. (Previously presented) The fusion protein of claim 54, wherein the fusion protein is encoded by plasmid pET65MP/NP-B or plasmid pET65MP/NP-D.

59. (Previously presented) The fusion protein of claim 54, wherein the antigen includes a CTL epitope.

60. (Canceled)

61. (Previously presented) A fusion protein comprising an antigen of an influenza virus, or an antigenic portion thereof, and a bacterial stress protein, or a portion thereof, wherein the antigen of the influenza virus is nucleoprotein, neuraminidase, M1, M2, PB1, PB2, or PA and the fusion protein induced an immune response against the antigen in a mammal to whom the fusion protein is administered.

62. (Previously presented) The fusion protein of claim 61, wherein the bacterial stress protein is a mycobacterial stress protein.

63. (Previously presented) A composition comprising the fusion protein of claim 54 and a pharmaceutically acceptable excipient, carrier, diluent, or vehicle.

64. (Previously presented) A method of inducing an immune response against an antigen of an influenza virus, the method comprising administering the fusion protein of claim 54 to a vertebrate in an amount effective to induce an immune response against the antigen.

65. (Previously presented) The method of claim 64, wherein the fusion protein is administered in combination with a pharmaceutically acceptable excipient, carrier, diluent, or vehicle.

66. (Previously presented) A method of inducing an immune response against an antigen of the influenza virus, the method comprising administering the fusion protein of claim 58 to a vertebrate in an amount effective to induce an immune response against the antigen.

67. (Previously presented) The method of claim 66, wherein the fusion protein is administered in combination with a pharmaceutically acceptable excipient, carrier, diluent, or vehicle.

68. (Previously presented) The fusion protein of claim 54, wherein the immune response is a cell mediated immune response.

69. (Previously presented) The fusion protein of claim 68, wherein the cell mediated immune response is a cell mediated cytolytic immune response.

70-87. (Canceled)

88. (Previously presented) The fusion protein of claim 68, wherein the cell mediated immune response is a class I-restricted T cell response.

89. (Previously presented) The fusion protein of claim 68, wherein the cell mediated immune response is a class II-restricted T cell response.

90. (Previously presented) The fusion protein of claim 59, wherein the CTL epitope is a class I-restricted T cell epitope.

91. (Previously presented) The fusion protein of claim 59, wherein the CTL epitope is a class II-restricted T cell epitope.

92. (Previously presented) The fusion protein of claim 62, wherein the stress protein is hsp65.

93. (Previously presented) The fusion protein of claim 62, wherein the stress protein is hsp71.

94. (Canceled)

95. (Previously presented) The method of claim 64, wherein the immune response is a cell mediated immune response.

96. (Previously presented) The method of claim 95, wherein the cell mediated immune response is a cell mediated cytolytic immune response.

97. (Previously presented) The method of claim 95, wherein the cell mediated immune response is a class I-restricted T cell response.

98. (Previously presented) The method of claim 95, wherein the cell mediated immune response is a class II-restricted T cell response.

99. (New) The fusion protein of claim 54, wherein the stress protein is a mammalian stress protein.

100. (New) The fusion protein of claim 99, wherein the mammalian stress protein is a human stress protein.

101. (New) The fusion protein of claim 61, wherein the bacterial stress protein is an enterobacterial stress protein.

102. (New) The fusion protein of claim 61, wherein the bacterial stress protein is an *E. coli* stress protein.

103. (New) The fusion protein of claim 62, wherein the mycobacterial stress protein is a stress protein of *Mycobacterium leprae, Mycobacterium tuberculosis*, or *Mycobacterium bovis.*

104. (New) The fusion protein of claim 54, wherein the stress protein is an Hsp100-200.

105. (New) The fusion protein of claim 104, wherein the Hsp100-200 is a Grp170.

106. (New) The fusion protein of claim 54, wherein the stress protein is an Hsp100.

107. (New) The fusion protein of claim 106, wherein the Hsp100 is a mammalian Hsp110, a yeast Hsp104, or a clpA, clpB, clpC, clpX or clpY stress protein.

108. (New) The fusion protein of claim 54, wherein the stress protein is an Hsp90.

109. (New) The fusion protein of claim 108, wherein the Hsp90 is a yeast Hsp83 or Hsc83 or a human Hsp90α, Hsp90β, or Grp94.

110. (New) The fusion protein of claim 54, wherein the stress protein is Lon.

111. (New) The fusion protein of claim 54, wherein the stress protein is an Hsp70.

112. (New) The fusion protein of claim 111, wherein the Hsp70 is a mammalian Hsp72 or Hsp73.

113. (New) The fusion protein of claim 54, wherein the stress protein is an Hsp60.

114. (New) The fusion protein of claim 54, wherein the stress protein is a TF55.

115. (New) The fusion protein of claim 54, wherein the stress protein is an Hsp40.

116. (New) The fusion protein of claim 54, wherein the stress protein is an FKBP.

117. (New) The fusion protein of claim 116, wherein the FKBP is FKBP12, FKBP13, FKBP25, FKBP59, Fpr1, or Nep1.

118. (New) The fusion protein of claim 54, wherein the stress protein is a cyclophilin.

119. (New) The fusion protein of claim 118, wherein the cyclophilin is cyclophilin A, cyclophilin B, or cyclophilin C.

120. (New) The fusion protein of claim 54, wherein the stress protein is an Hsp20-30.

121. (New) The fusion protein of claim 120, wherein the Hsp20-30 is a Tcp1, TriC, or thermosome.

122. (New) The fusion protein of claim 54, wherein the stress protein is a ClpP.

123. (New) The fusion protein of claim 54, wherein the stress protein is a GrpE.

124. (New) The fusion protein of claim 54, wherein the stress protein is an Hsp10.

125. (New) The fusion protein of claim 124, wherein the Hsp10 is GroEs or Cpn10.

126. (New) The fusion protein of claim 54, wherein the stress protein is a ubiquitin, calnexin, or protein disulfide isomerase.

127. (New) The fusion protein of claim 61, wherein the bacterial stress protein is an Hsp90, Hsp70, Hsp60, Hsp40, or Hsp10.

128. (New) The fusion protein of claim 127, wherein the Hsp90 is an HtpG.

129. (New) The fusion protein of claim 127, wherein the Hsp70 is a DnaK.

130. (New) The fusion protein of claim 127, wherein the Hsp60 is an hsp65 or GroEL.

131. (New) The fusion protein of claim 127, wherein the Hsp40 is a DnaJ.

132. (New) The fusion protein of claim 127, wherein the Hsp10 is a GroES.

133. (New) The fusion protein of claim 54, wherein the antigen of the influenza virus is neuraminidase.

134. (New) The fusion protein of claim 54, wherein the antigen of the influenza virus is M1 or M2.

135. (New) The fusion protein of claim 54, wherein the antigen of the influenza virus is PB1, PB2, or PA.